Monday, 27 June 2022


Shionogi’s COVID-19 antiviral drug shows rapid virus clearance

28 April 2022 | News

The drug shortened infectious virus shedding by 1-2 days versus placebo

Image credit: shutterstock

Image credit: shutterstock

Japan-based Shionogi & Co., Ltd. announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, 23 – 26 April. S-217622 is an investigational 3CL protease inhibitor that was studied for once-daily oral administration in mainly vaccinated patients (~85%), with no risk factors for severe complications, within five days of COVID-19 symptom onset.

At the meeting, Shionogi presented new late-breaking Phase 2b results from the Phase 2/3 clinical trial of S-217622, completed in Asia.

These new data showed S-217622 demonstrated rapid clearance of the infectious SARS-CoV-2 virus.

On day four of treatment (following the third dose), the proportion of patients with positive viral titer decreased by approximately 90% versus placebo.

S-217622 shortened infectious virus shedding by 1-2 days versus placebo.

S-217622 showed a significant reduction in viral RNA on days 2, 4, 6 and 9 versus placebo (difference versus placebo in the Least Squares mean change from baseline in viral RNA; under -1.0 logx copies/mL on day four at each dose).

There was no significant difference in total score of 12 COVID-19 symptoms between treatment arms, however, S-217622 showed improvement in composite score of five “respiratory and feverish” symptoms (post-hoc analysis).

 

A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account